Stay updated with breaking news from Activating Construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor... | June 19, 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and... | April 17, 2023
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic...
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective reduced by Canaccord Genuity Group from $16.00 to $8.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Other analysts also recently issued research reports about the stock. HC Wainwright decreased their price […]
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Stock analysts at Cantor Fitzgerald upped their FY2023 earnings per share estimates for Harpoon Therapeutics in a report released on Wednesday, March 29th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will post earnings of ($1.11) per share for the year, up from their prior […]